Loading
A phase 1/2 trial of JSKN003 in advanced solid tumours, run by Jiangsu Alphamab Biopharmaceuticals Co., Ltd, active and no longer recruiting.
Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05744427 by Jiangsu Alphamab Biopharmaceuticals Co., Ltd, with 725 participants enrolled, started 2023-03-15 and due to reach its primary completion in 2026-07-30. Interventions recorded: JSKN003.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Alphamab Oncology, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/